In a much anticipated pipeline update, GlaxoSmithKline says it plans to launch five major vaccines over the next five years that have a potential market value of $11 billion to $18 billion by 2010. At the top of the pipeline are Cervarix and Rotarix -- both the subject of ongoing talks with the FDA -- followed by Streptorix for pneumococcal disease. GSK also discussed plans to double its output of flu vaccine in the wake of the Chiron closure during the last flu season.
- read this story from MarketWatch for more